Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists — Hanis Hanum Zulkifly (2023) | RDL Network
Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists
Article 2023 en
Authors
HZ
Hanis Hanum Zulkifly
DP
Daniele Pastori
DL
Deirdre A. Lane
Abstract
1 min read
Operated valvular heart disease patients with AF at baseline have poorer anticoagulation control compared to those without AF. The presence of concomitant AF, anaemia/bleeding history and female sex independently predicted poor TTR. Stringent INR monitoring is needed to improve anticoagulation control and prevent major adverse clinical events in patients with operated valvular heart disease.
José María Lobos-Bejarano, Ángel Castellanos Rodríguez, Vivencio Barrios, Carlos Escobar, José Polo García, José Carlos del Castillo-Rodríguez, Diego Vargas-Ortega, Adriana López‐Pineda, Luís Prieto, Professor Gregory Lip
María Asunción Esteve‐Pastor, José Miguel Rivera‐Caravaca, Inmaculada Roldán‐Rabadán, Vanessa Roldán, Javier Muñiz, Paula Raña‐Míguez, Martín Ruiz Ortiz, Ángel Cequier, Vicente Bertoméu, Lina Badimón, Manuel Anguita, Professor Gregory Lip, Francisco Marı́n
Discussion(0)
No comments yet. Be the first to comment.